Plasma visfatin/nicotinamide phosphoribosyltransferase levels in hypertensive elderly - results from the PolSenior substudy

Abstract

Visfatin/nicotinamide phosphoribosyltransferase (NAMPT), is a 52 kDa adipokine with proinflammatory properties produced mostly by macrophages and adipocytes from visceral adipose tissue. It seems that visfatin/NAMPT plays a role in the pathogenesis of arterial hypertension. As this condition is frequently present in the elderly, the aim of the study was to assess the plasma visfatin/NAMPT levels in normotensive and hypertensive subjects from the Polish elderly population. Visfatin/NAMPT levels were measured by specific enzyme-linked immunosorbent assay method in plasma samples from 2789 elderly subjects (1338 females, 1451 males) without heart failure, the PolSenior study participants, in addition to previously estimated serum concentrations of insulin, glucose, creatinine, C-reactive protein, and interleukin-6. Homeostasis model assessment for insulin resistance was calculated and used as a marker of insulin resistance. In the study group, 591 subjects were normotensive, 449 had untreated hypertension, and 1749 had treated hypertension. Plasma visfatin/NAMPT levels were not related to the presence of hypertension or the use of antihypertensive drugs, including angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists. The regression analysis revealed that plasma visfatin/NAMPT concentration variability is increased in subjects with high-sensitivity C-reactive protein concentration above 3 mg/L and with homeostasis model assessment for insulin resistance ≥2.5, and decreased in those aged over 80 years. Our study shows that the presence of hypertension is not associated with the plasma levels of visfatin/NAMPT in elderly subjects. Plasma visfatin/NAMPT concentrations positively correlate with inflammation and insulin resistance, and are decreased in the oldest.

Keywords: Aging; antihypertensive treatment; hypertension; microinflammation.